In short. Exosome marketing usually rests on cells in a dish, animal models or a case series from one clinic. Each design can establish something, and none establishes that an injected product changes a human face, because delivery, dose and persistence are not tested in a dish and a needling or laser procedure is usually done at the same time.
Key points
- A dish can show a mechanism is possible under controlled conditions.
- An animal can show an effect in a system that is not yours.
- A case series can show only that a clinician believes something happened.
- A needling or laser done at the same time confounds the result.
- Marketed material is not the characterised material the research used.
Three kinds of study, three different claims
When a claim about exosomes is challenged, the support offered is usually one of three things: work in cells in a dish, work in animals, or a series of patients treated at one clinic. Each can establish something, and none can establish what a marketing claim needs.
Cells in a dish
An in-vitro experiment can show that a preparation changes the behaviour of cells under controlled conditions, which is a real finding and where most of this field starts.
What a dish cannot show
What it cannot show is whether anything comparable happens in living skin: a dish has no barrier to cross, no blood supply, no immune response and no clearance, so delivery, dose and persistence, the questions that decide whether a treatment does anything, go unanswered.
Animal models
Animal work adds a living system, and with it a set of differences. Skin thickness, healing behaviour and immune response vary between species, and a rodent heals with a speed and a scar pattern that no human does. A positive result in an animal model is a reason to test in people rather than evidence of what will happen in them, and the history of medicine records how often that translation fails.
Case series
A case series is a report of patients treated by one clinician, described by that clinician, with no comparison group and no blinding. It is the weakest of the three designs and the one most often presented as proof, because it looks like a result: photographs, patient accounts, a change over time. What it cannot separate is the treatment from everything else that changed: skin improves over months on its own, and a patient who paid for a treatment and returns to the clinic that gave it has reasons to report improvement.
The co-intervention problem
These products are usually applied immediately after a procedure that deliberately injures the skin, such as microneedling or a fractional laser. That procedure produces changes by itself, and those are exactly the changes the product is credited with. Nothing in a case series separates the two, and no fee arrangement gives a clinic an incentive to try.
| Design | What it can establish | What it cannot establish | Main confound |
|---|---|---|---|
| Cells in a dish | That a preparation changes cell behaviour under controlled conditions | Delivery, dose or persistence in living skin | No barrier, blood supply, immune response or clearance |
| Animal model | An effect in a living system | What will happen in human skin | Species differ in thickness, healing and immune response |
| Case series | That one clinician reports a change | That the treatment caused it | No comparison group and no blinding |
| Case series with needling or laser | A result after a combined procedure | Which of the two produced it | The procedure changes the skin by itself |
| Research material compared with a marketed product | Findings about characterised material | Findings about the product being sold | Content and confirming assays differ |
Which questions separate the designs?
Was there a comparison group, or only a series of treated patients? Who assessed the outcome, and did they know which treatment had been given? Was the injected material the only thing that changed, or was a needling or laser done at the same time? Those three questions separate the designs more quickly than the length of a paper or the reputation of a clinic.
How can a reader tell what a claim rests on?
Ask which of the three designs the claim comes from, then apply the three questions. A photograph and a patient account are not a comparison group. A paper that reports cells in a dish has not reported a face. Where the design is a case series and a needling or laser was performed at the same visit, the result cannot be attributed to the product.
A marketed product is not the material studied
Research on exosomes uses material produced and characterised for the purpose, at a stated content and with confirming assays. A marketed product is not that material, so the studies may be sound and still describe something other than what is sold.
Sources
- American Society of Plastic Surgeons: guidance on the evidence base for injectable treatments
- Cochrane Library: systematic reviews on skin rejuvenation interventions
- National Institute for Health and Care Excellence: guidance on unlicensed injectable products
Source links open each organisation's search results for the topic. Document-level confirmation is pending the reviewer's sign-off.
Internal links
Frequently asked questions
What can an in-vitro study of exosomes establish?
That a preparation changes the behaviour of cells under controlled laboratory conditions. That is a genuine finding and it is where most of this field begins. It cannot show whether anything comparable happens in living skin, because a dish has no barrier to cross, no blood supply, no immune response and no clearance. Delivery, dose and persistence are not answered in a dish.
Why does an animal study not predict what happens in a face?
Because skin thickness, healing behaviour and immune response differ between species, and a rodent heals with a speed and a scar pattern that no human does. A positive result in an animal is a reason to test in people. It is not evidence of what will happen in people, and the history of medicine is largely a record of how often that step fails.
What is the strongest study design used in exosome marketing?
Usually a case series: patients treated by one clinician, described by that clinician, with no comparison group and no blinding. It is the weakest of the three designs and the one most often presented as proof, because it produces photographs and patient accounts that look like a result. What it cannot do is separate the treatment from everything else that changed.
Risks & Limitations
- No product marketed as an exosome injectable has been through the approval process that would establish what it contains or what it does.
- Birth tissue derived material carries an infection risk when it is injected, and serious infections have been reported after such injections.
- The evidence behind most claims comes from laboratory work, animal models or uncontrolled case series, none of which establishes an effect in people.
- Regulatory status differs by country, and in most markets there is no approval for these products in any injectable use.
- Nothing on this site is a recommendation for or against any treatment, and it does not assess individual cases.
When to Seek Care
- Spreading redness, heat, swelling or discharge at an injection site: have it assessed promptly.
- Fever, or feeling unwell with a painful injected area: seek medical care without waiting.
- Severe or worsening pain, blistering, or skin breakdown where something was injected.
- Any new and persistent symptom after a treatment: have it assessed by a clinician who can examine you.
References & Further Reading
- American Society of Plastic Surgeons (ASPS) — procedure and safety guidance
- National Institute for Health and Care Excellence (NICE, UK) — relevant guidance
- Cochrane Library — systematic reviews
- Chinese Medical Association Plastic Surgery Branch — clinical guidance
This page is patient education, not medical advice, and it does not cite individual studies. It reviews evidence and regulation; it is not a booking page and does not recommend a treatment. Discuss your own case with a qualified clinician. To ask a question about this review, see Contact & Consultation.